Evaluation the effect of N Acetyl Cystein (NAC) in myocardial infarction

Evaluation the effects of N Acetyl Cysteine (NAC) in myocardial reperfusion of patients with STEMI undergoing to P-PCI in Karaj's Shahid Rajayi hospital in 2020

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200519047506N1

Enrollment

142

Registered

2020-09-18

Start date

2020-07-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: 1200 mg N Acetyl Cysteine prior to primary PCI and every 12 hour for 48 hour will be injected intravenously. Intervention 2: Control group: 100 cc serum dextrose 5

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted at Shahid Rajaii hospital in karaj in 2020 Patients admitted with myocardial infarction Patients who had STEMI Patients candidate for Primary PCI

Exclusion criteria

Exclusion criteria: Patients who have renal failure Patients who have allergy to N Acetyl Cystein Patients who have asthma

Design outcomes

Primary

Measure	Time frame
Troponin level. Timepoint: Prior to intervention, 24 hour and 48 hour after intervention. Method of measurement: Blood test.;Creatine kinase MB level. Timepoint: Prior to intervention and 24 hour and 48 hour after intervention. Method of measurement: Blood test.;Blood Urea. Timepoint: Prior to intervention and 24 hour after intervention. Method of measurement: Blood test.;Ejection Fraction. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Left ventricle end systolic volume. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Left ventricle end diastolic volume. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Blood creatinine. Timepoint: Prior to intervention and 24 hour after intervention. Method of measurement: Blood test.;Thrombolysis in myocardial infarction. Timepoint: Prior to and after intervention. Method of measurement: Angiography.;Corrected thrombolysis in myocardial infarction frame count. Timepoint: After intervention. Method of measurement: Angiography.	—

Measure

Time frame

Troponin level. Timepoint: Prior to intervention, 24 hour and 48 hour after intervention. Method of measurement: Blood test.;Creatine kinase MB level. Timepoint: Prior to intervention and 24 hour and 48 hour after intervention. Method of measurement: Blood test.;Blood Urea. Timepoint: Prior to intervention and 24 hour after intervention. Method of measurement: Blood test.;Ejection Fraction. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Left ventricle end systolic volume. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Left ventricle end diastolic volume. Timepoint: After intervention and 1 month after discharge. Method of measurement: Echocardiography.;Blood creatinine. Timepoint: Prior to intervention and 24 hour after intervention. Method of measurement: Blood test.;Thrombolysis in myocardial infarction. Timepoint: Prior to and after intervention. Method of measurement: Angiography.;Corrected thrombolysis in myocardial infarction frame count. Timepoint: After intervention. Method of measurement: Angiography.

—

Secondary

Measure	Time frame
Mortality. Timepoint: After 6 month. Method of measurement: Asking by telephone call.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHuma Arabi

Alborz University of Medical Science

miss.arabi@yahoo.com+98 21 4446 0486

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026